Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Cyclopentanohydrophenanthrene ring system doai
Patent
1997-12-19
1999-11-23
Clardy, S. Mark
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Cyclopentanohydrophenanthrene ring system doai
514173, 514176, 514179, 514180, 514182, A61K 3158, A61K 3156
Patent
active
059900997
ABSTRACT:
Compositions of angiostatic agents for treating GLC1A glaucoma and methods for their use are disclosed.
REFERENCES:
patent: 4642355 (1987-02-01), Nakamura et al.
patent: 4863912 (1989-09-01), Southren et al.
patent: 4876250 (1989-10-01), Clark
patent: 5371078 (1994-12-01), Clark et al.
patent: 5606043 (1997-02-01), Nguyen et al.
patent: 5698545 (1997-12-01), Clark et al.
Sommer A, et al. Relationship between intraocular pressure and primary open angle glaucoma among white and black Americans. Arch. Ophthalmol. 109:1090-1095, (1991).
Sheffield, et al., "Genetic Linkage of Familial Open Angle Glaucoma to Chromosome 1q21-131," Nature Genetics, 4:47-50 (1993).
Sarfarazi, et al., "Assignment of a Locus (GLC3A) for Primary Congenital Glaucoma (Buphthalmos) to 2p21 and Evidence for Genetic Heterogeneity," Genomics, 30:171-177 (1995).
Akarsu, et al.,"A Second Locus (GLC3B) for Primary Congenital Glaucoma (Buphthalmos) Maps to the 1p36 Region," Human Molecular Genetics, 5(8):1199-1203 (1996).
Stoilova, et al., "Localization of a Locus (GLC1B) for Adult-Onset Primary Open Angle Glaucoma to the 2cen-q13 Region," Genomics, 36:142-150 (1996).
Wirtz, et al., "Mapping a Gene for Adult-Onset Primary Open-Angle Glaucoma to Chromosome 3q," Am. J. Hum. Genet., 60:296-304 (1997).
Andersen, et al., "A Gnee Responsible for the Pigment Dispersion Syndrome Maps to Chromosome 7q35-q36," Arch. Ophthalmol., 115:384-388 (1997).
Richards, et al., "Mapping of a Gene for Autosomal Dominant Juvenile-Onset Open-Angle Glaucome to Chromosome 1q," Am. J. Hum. Genet., 54:62-70 (1994).
Morissette, et al., "A Common Gene for Juvenile and Adult-Onset Primary Open-Angle Glaucomas Confined on Chromosome 1q," Am. J. Hum. Genet., 56:1431-1442 (1995).
Wiggs, et al., "Genetic Linkage of Autosomal Dominant Juvenile Glaucoma to 1q21-q31 in Three Affected Pedigrees," Genomics, 21:299-303 (1994).
Meyer, et al., "Age-Dependent Penetrance and Mapping of the Locus for Juvenile and Early-Onset Open-Angle Glaucoma on Chromosome 1q (GLC1A) in a French Family," Hum. Genet., 98:567-571 (1996).
Graff, et al., "Confirmation of Linkage to 1q21-31 in a Danish Autosomal Dominant Juvenile-Onset Glaucoma Family and Evidence of Genetic Heterogeneity," Hum. Genet., 96:285-289 (1995).
Stone, et al., "Identification of a Gene That Causes Primary Open Angle Glaucoma," Science, 275:668-670 (1997).
Polansky, et al., "Eiconsanoid Production and Glucocorticoid Regulatory Mechanisms in Cultured Human Trabecular Meshwork Cells," The Ocular Effects of Prostaglandins and Other Eicosanoids, pp. 113-138 (1989).
Polansky, et al., "In Vitro Correlates of Glucocorticoid Effects on Intraocular Pressure," Glaucoma Update IV (1991).
Polansky, et al., "Cellular Pharmacology and Molecular Biology of the Trabecular Meshwork Inducible Glucocorticoid Response Gene Product," Ophthalmologica, 211:126-139 (1997).
Ortego, et al., "Cloning and Characterization of Subtracted cDNAs from a Human Ciliary Body Library Encoding TIGR, a Protein Involved in Juvenile Open Angle Glaucoma with Homology to Myosin and Olfactomedin," FEBS Letters, 413:349-353 (1997).
(Kubota, et al., "A Novel Myosin-like Protein (Myocilin) Expressed in the Connecting Cilium of the Photoreceptor: Molecular Cloning, Tissue Expression, and Chromosomal Mapping," Genomics, 41:360-369 (1997).
DeSantis, et al., Dexamethasone-Induction of Ocular Hypertension in the Primate, ARVO Abstracts. Invest. Ophthalmol. Vis. Sci., 31(Suppl.):99 (1990).
Knepper, et al., "Intraocular Pressure and Glycosaminoglycan Distribution in the Rabbit Eye: Effect of Age and Dexamethasone," Exp. Eye Res., 27:567-565 (1978).
Francois, et al., Ultrastructural and Morphometric Study of Corticosteroid Glaucoma in Rabbits, Ophthalmic Res., 16:168-178 (1984).
Lorenzetti, O. J., "Effects of Corticosteroids on Ocular Dynamics in Rabbits," J. Pharmacol. Exp. Therap., 175:763-772 (1970).
Zhan, et al., "Steroid Glaucoma: Corticosteroid-Induced Ocular Hypertension in Cats," Exp. Eye Res., 54:211-218 (1992).
Rozsival, et al., "Aqueous Humour and Plasma Cortisol Levels in Glaucoma and Cataract Patients," Current Eye Research, 1:391-396 (1981).
Ray, et al., "Plasma Cortisol in Glaucoma," Ann. Ophthalmol., 9:1151-1154 (1977).
Schwartz, et al., "Increased Plasma Free Cortisol in Ocular Hypertension and Open Angle Glaucoma," Arch. Ophthalmol., 105:1060-1065 (1987).
Wilson, et al., Dexamethasone Induced Ultrastructural Changes in Cultured Human Trabecular Meshwork Cells, Cur. Eye Res., 12:784-793 (1993).
Clark, et al., "Glucocorticoid-Induced Formation of Cross-Linked Actin Networks in Cultured Human Trabecular Meshwork Cells," Invest. Ophthalmol. Vis. Sci., 35:281(1994).
Crum, et al., "A New Class of Steroids Inhibits Angiogenesis in the Presence of Heparin or a Heparin Fragment," Science, 230:1375-1378 (Dec. 20, 1985).
Ingber, et al., "A Possible Mechanism for Inhibition of Angiogenesis by Angiostatic Steroids: Induction of Capiullary Basement Membrane Dissolution," Endocrinology, 119:1768-1775 (1986).
Southren, et al., "Intraocular Hypotensive Effect of a Topically Applied Cortisol Metalolite: 3-alpha, 5-beta-tetrahydrocortisol," Investigative Ophthalmology and Visual Science, (May 28, 1987.
Folkman, et al., "Angiostatic Steroids," Ann. Surg., 206(3) (1987).
Alcon Laboratories Inc.
Clardy S. Mark
Pryor Alton
Yeager Sally
LandOfFree
Angiostatic agents and methods and compositions for controlling does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Angiostatic agents and methods and compositions for controlling , we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Angiostatic agents and methods and compositions for controlling will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1222038